Hydrochlorothiazidum Polpharma (Hydrochlorothiazide)

Hydrochlorothiazidum Polpharma is indicated for several clinical situations where fluid balance and blood pressure control are required.

• Management of hypertension, either as monotherapy or in combination with other antihypertensive agents.
• Reduction of edema associated with congestive heart failure, hepatic cirrhosis, or chronic kidney disease.
• Adjunctive therapy to prevent recurrence of calcium‑containing kidney stones.
• Short‑term control of fluid overload in patients undergoing surgery or with acute pulmonary edema.
• Off‑label use may include treatment of hypercalcemia under specialist supervision.

• Hydrochlorothiazide acts by inhibiting the sodium‑chloride symporter located in the distal convoluted tubule of the nephron. This blockade reduces sodium reabsorption, leading to increased excretion of sodium and water, which decreases plasma volume. The resulting reduction in extracellular fluid contributes to lower blood pressure, while the enhanced calcium reabsorption in the renal tubule helps prevent calcium‑based kidney stone formation.

Hydrochlorothiazidum Polpharma may cause a range of adverse reactions, some of which are more frequently observed than others.

Common

• Electrolyte disturbances such as low potassium (hypokalemia) or low sodium (hyponatremia).
• Increased urination (polyuria) and associated dehydration.
• Dizziness or light‑headedness, especially when standing.
• Mild gastrointestinal upset, including nausea or abdominal cramps.
• Elevated blood glucose levels in susceptible individuals.

Serious

• Severe electrolyte imbalances leading to cardiac arrhythmias.
• Acute gout attacks triggered by rising uric acid levels.
• Pancreatitis or severe allergic reactions (e.g., Stevens‑Johnson syndrome).
• Significant drops in blood pressure causing syncope.
• Renal impairment or worsening of pre‑existing kidney disease.

Before initiating Hydrochlorothiazidum Polpharma, certain safety considerations should be reviewed.

• Assess baseline electrolyte levels and renal function, especially in patients with chronic kidney disease.
• Use cautiously in individuals with a history of gout, as uric acid may increase.
• Monitor blood glucose in diabetic patients, as thiazides can raise glucose concentrations.
• Evaluate for potential hypersensitivity reactions, particularly in patients with known sulfonamide allergy.
• Consider dose adjustments in the elderly or those with hepatic impairment.
• Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness.

Hydrochlorothiazidum Polpharma can interact with several other medicines, influencing efficacy or safety.

Avoid

• Concurrent use with other potent diuretics or lithium, which may increase risk of toxicity.
• Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can blunt diuretic effect and impair renal function.
• Combining with ACE inhibitors or ARBs without careful monitoring, as excessive potassium loss may occur.

Use with caution

• Antihypertensive agents (beta‑blockers, calcium channel blockers) may enhance blood pressure lowering.
• Antidiabetic drugs, as thiazides can raise blood glucose, requiring dose adjustments.
• Anticoagulants, because altered plasma volume may affect drug concentration.
• Corticosteroids, which may exacerbate fluid retention and electrolyte disturbances.